Sign up to save your podcasts
Or
Share Episode 373: 384. Chronic Kidney Disease and Empagliflozin Legacy Effect
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Episode 373: 384. Chronic Kidney Disease and Empagliflozin Legacy Effect
What Was Studied?
The EMPA-KIDNEY trial followed 6,609 CKD patients at risk of disease progression. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo for a median of 2 years. After this ‘active’ phase, 4,891 patients entered a 2-year post-trial observational period where neither group received the trial drug, but doctors could prescribe open-label SGLT2 inhibitors. The goal? To see if empagliflozin’s benefits persisted after stopping treatment.
Key Findings
Sustained Kidney Protection:
Over the entire 4-year period (active + post-trial), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 21% (HR 0.79). The number needed to treat (NNT) to prevent one event was 24 patients over 4 years.
Over the entire 4-year period (active + post-trial), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 21% (HR 0.79). The number needed to treat (NNT) to prevent one event was 24 patients over 4 years.
Post-Trial Benefits:
Even after stopping the drug, the empagliflozin group saw a 13% lower risk of the primary outcome during the post-trial phase alone (HR 0.87).
Even after stopping the drug, the empagliflozin group saw a 13% lower risk of the primary outcome during the post-trial phase alone (HR 0.87).
Specific Outcomes:
Kidney disease progression: 23.5% (empagliflozin) vs. 27.1% (placebo).
Death or end-stage kidney disease: 16.9% vs. 19.6%.
Cardiovascular death: 3.8% vs. 4.9%.
Safety: No increased risk of noncardiovascular deaths (5.3% in both groups).
Limitations
Observational Post-Trial Phase: After the active trial, 40-43% of both groups used open-label SGLT2 inhibitors, potentially diluting the observed benefit.
Selection Bias: Only 74% entered post-trial follow-up, and outcomes relied on local lab data (not centralized measurements).
Short Post-Trial Window: Effects beyond 2 years post-discontinuation remain unknown.
Should This Change Practice?
Yes. Here’s why:
Longer-Term Reassurance: Empagliflozin’s benefits persist for ~1 year after stopping, supporting its role even if patients discontinue it later.
Broad Applicability: The trial included diverse CKD patients, not just those with diabetes.
Strong Safety Signal: No excess noncardiovascular deaths—critical for chronic conditions requiring lifelong management.
For clinicians, this reinforces SGLT2 inhibitors as a first-line therapy for CKD, regardless of diabetes status. The modest NNT (24 over 4 years) highlights its clinical meaningfulness in a high-risk population.
View all episodes
By Questioning Medicine
4.9
7171 ratings
What Was Studied?
The EMPA-KIDNEY trial followed 6,609 CKD patients at risk of disease progression. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo for a median of 2 years. After this ‘active’ phase, 4,891 patients entered a 2-year post-trial observational period where neither group received the trial drug, but doctors could prescribe open-label SGLT2 inhibitors. The goal? To see if empagliflozin’s benefits persisted after stopping treatment.
Key Findings
Sustained Kidney Protection:
Over the entire 4-year period (active + post-trial), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 21% (HR 0.79). The number needed to treat (NNT) to prevent one event was 24 patients over 4 years.
Over the entire 4-year period (active + post-trial), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 21% (HR 0.79). The number needed to treat (NNT) to prevent one event was 24 patients over 4 years.
Post-Trial Benefits:
Even after stopping the drug, the empagliflozin group saw a 13% lower risk of the primary outcome during the post-trial phase alone (HR 0.87).
Even after stopping the drug, the empagliflozin group saw a 13% lower risk of the primary outcome during the post-trial phase alone (HR 0.87).
Specific Outcomes:
Kidney disease progression: 23.5% (empagliflozin) vs. 27.1% (placebo).
Death or end-stage kidney disease: 16.9% vs. 19.6%.
Cardiovascular death: 3.8% vs. 4.9%.
Safety: No increased risk of noncardiovascular deaths (5.3% in both groups).
Limitations
Observational Post-Trial Phase: After the active trial, 40-43% of both groups used open-label SGLT2 inhibitors, potentially diluting the observed benefit.
Selection Bias: Only 74% entered post-trial follow-up, and outcomes relied on local lab data (not centralized measurements).
Short Post-Trial Window: Effects beyond 2 years post-discontinuation remain unknown.
Should This Change Practice?
Yes. Here’s why:
Longer-Term Reassurance: Empagliflozin’s benefits persist for ~1 year after stopping, supporting its role even if patients discontinue it later.
Broad Applicability: The trial included diverse CKD patients, not just those with diabetes.
Strong Safety Signal: No excess noncardiovascular deaths—critical for chronic conditions requiring lifelong management.
For clinicians, this reinforces SGLT2 inhibitors as a first-line therapy for CKD, regardless of diabetes status. The modest NNT (24 over 4 years) highlights its clinical meaningfulness in a high-risk population.
More shows like Questioning Medicine
View all
Best Science Medicine Podcast - BS without the BS
167 Listeners
Medicine and Science from The BMJ
42 Listeners
Planet Money
30,853 Listeners
JAMA Clinical Reviews
488 Listeners
AFP: American Family Physician Podcast
695 Listeners
ChooseFI
5,084 Listeners
White Coat Investor Podcast
2,416 Listeners
The Curbsiders Internal Medicine Podcast
3,317 Listeners
The Daily
112,857 Listeners
The Five
3,882 Listeners
Up First from NPR
56,209 Listeners
The Peter Attia Drive
7,782 Listeners
Post Reports
5,425 Listeners
The Clinical Problem Solvers
506 Listeners
The Ezra Klein Show
14,859 Listeners